Orexo acquires US rights to digital therapy for alcohol use disorder

Orexo acquires US rights to digital therapy for alcohol use disorder
Credit: Shutterstock.com/ Atstock Productions

Orexo, a speciality pharma company based in Sweden, has acquired the exclusive US rights to vorvida, a digital therapy for the treatment of alcohol use disorder (AUD), from digital therapeutics specialist GAIA.

This follows an earlier agreement with GAIA in August 2019 for the exclusive global commercial rights to OXD01, a new digital therapy being developed for the treatment of opioid use disorder (OUD).

As per this new agreement, Orexo will be responsible for the regulatory approval and commercialisation of vorvida in the US, whilst GAIA will be entitled to an upfront payment, milestone payments as well as royalties.

The two companies will initiate a dialog with the FDA about the regulatory pathway, the outcome of which will decide the launch timing and requirement for additional investments in the development of vorvida for the US market.